These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 36685594)

  • 1. Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition.
    Tao S; Liang S; Zeng T; Yin D
    Front Immunol; 2022; 13():1043667. PubMed ID: 36685594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinatorial targeting of immune checkpoints and epigenetic regulators for hepatocellular carcinoma therapy.
    Akce M; El-Rayes BF; Wajapeyee N
    Oncogene; 2023 Mar; 42(14):1051-1057. PubMed ID: 36854723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
    Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
    Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy.
    Li Q; Han J; Yang Y; Chen Y
    Front Immunol; 2022; 13():1070961. PubMed ID: 36601120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data.
    Harkus U; Wankell M; Palamuthusingam P; McFarlane C; Hebbard L
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):799-815. PubMed ID: 35065242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses.
    Yuen VW; Chiu DK; Law CT; Cheu JW; Chan CY; Wong BP; Goh CC; Zhang MS; Xue HD; Tse AP; Zhang Y; Lau HY; Lee D; Au-Yeung RKH; Wong CM; Wong CC
    J Hepatol; 2023 Feb; 78(2):376-389. PubMed ID: 36455783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the role of the immune microenvironment in hepatocellular carcinoma: Implications for immunotherapy and drug resistance.
    Fu Y; Guo X; Sun L; Cui T; Wu C; Wang J; Liu Y; Liu L
    Elife; 2024 Aug; 13():. PubMed ID: 39146202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100328. PubMed ID: 33549983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma.
    Kou L; Xie X; Chen X; Li B; Li J; Li Y
    Cancer Immunol Immunother; 2023 Dec; 72(12):3953-3969. PubMed ID: 37917364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
    Chen Y; Hu H; Yuan X; Fan X; Zhang C
    Front Immunol; 2022; 13():896752. PubMed ID: 35757756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitor resistance in hepatocellular carcinoma.
    Wang Z; Wang Y; Gao P; Ding J
    Cancer Lett; 2023 Feb; 555():216038. PubMed ID: 36529238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma.
    Dal Bo M; De Mattia E; Baboci L; Mezzalira S; Cecchin E; Assaraf YG; Toffoli G
    Drug Resist Updat; 2020 Jul; 51():100702. PubMed ID: 32371296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma.
    Chami P; Diab Y; Khalil DN; Azhari H; Jarnagin WR; Abou-Alfa GK; Harding JJ; Hajj J; Ma J; El Homsi M; Reyngold M; Crane C; Hajj C
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapies for hepatocellular carcinoma.
    Llovet JM; Castet F; Heikenwalder M; Maini MK; Mazzaferro V; Pinato DJ; Pikarsky E; Zhu AX; Finn RS
    Nat Rev Clin Oncol; 2022 Mar; 19(3):151-172. PubMed ID: 34764464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Roles of Epigenetic Regulation and the Tumor Microenvironment in the Mechanism of Resistance to Systemic Therapy in Hepatocellular Carcinoma.
    Oura K; Morishita A; Hamaya S; Fujita K; Masaki T
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current status and future of targeted-immune combination for hepatocellular carcinoma.
    Hao L; Li S; Ye F; Wang H; Zhong Y; Zhang X; Hu X; Huang X
    Front Immunol; 2024; 15():1418965. PubMed ID: 39161764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond.
    Feng MY; Chan LL; Chan SL
    Curr Oncol; 2022 Aug; 29(8):5489-5507. PubMed ID: 36005172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma.
    Akbulut Z; Aru B; Aydın F; Yanıkkaya Demirel G
    Front Immunol; 2024; 15():1379622. PubMed ID: 38638433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?
    Uson Junior PLS; Nagalo BM; Ahn DH; Bekaii-Saab T; Borad MJ
    Semin Liver Dis; 2021 May; 41(2):136-141. PubMed ID: 33957697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.